Biophytis is a biotechnology business based in the US. Biophytis shares (BPTS) are listed on the NASDAQ and all prices are listed in US Dollars. Biophytis employs 26 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Biophytis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BPTS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Biophytis stock price (NASDAQ: BPTS)
Use our graph to track the performance of BPTS stocks over time.Biophytis shares at a glance
Latest market close | $1.09 |
---|---|
52-week range | $0.94 - $10.99 |
50-day moving average | $1.41 |
200-day moving average | $4.25 |
Wall St. target price | $15.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.78 |
Buy Biophytis shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Biophytis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biophytis price performance over time
Historical closes compared with the close of $1.09 from 2022-07-01
1 week (2022-06-24) | 0.93% |
---|---|
1 month (2022-06-03) | -4.39% |
3 months (2022-04-01) | -50.00% |
6 months (2022-01-03) | -79.59% |
1 year (2021-07-02) | -88.85% |
---|---|
2 years (2020-06-29) | N/A |
3 years (2019-06-29) | N/A |
5 years (2017-06-29) | N/A |
Biophytis financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -52.81% |
Return on equity TTM | -783.82% |
Profit margin | 0% |
Book value | $0.42 |
Market capitalisation | $18.5 million |
TTM: trailing 12 months
Biophytis share dividends
We're not expecting Biophytis to pay a dividend over the next 12 months.
You may also wish to consider:
- CVS Health (CVS.US) (2.34% forward annual dividend yield)
- UnitedHealth Group Incorporated (UNH.US) (1.28% forward annual dividend yield)
- McKesson Corporation (MCK.US) (0.58% forward annual dividend yield)
Biophytis share price volatility
Over the last 12 months, Biophytis's shares have ranged in value from as little as $0.94 up to $10.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biophytis's is 1.4205. This would suggest that Biophytis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Biophytis's beta into context you can compare it against those of similar companies.
- CVS Health (CVS.US): 0.7722
- UnitedHealth Group Incorporated (UNH.US): 0.8339
- McKesson Corporation (MCK.US): 0.6597
Biophytis overview
Biophytis S. A. , a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.
Biophytis in the news

Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million

Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress

Biophytis: Results of the Combined General Meeting on June 21, 2022
Frequently asked questions
What percentage of Biophytis is owned by institutions?Currently 1.507% of Biophytis shares are held by institutions. How many people work for Biophytis?
Latest data suggests 26 work at Biophytis. When does the fiscal year end for Biophytis?
Biophytis's fiscal year ends in December. Where is Biophytis based?
Biophytis's address is: Sorbonne University, Paris, France, 75005 What is Biophytis's ISIN number?
Biophytis's international securities identification number is: US09076G1040
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert